Dimensional Fund Advisors LP grew its position in Alkermes PLC (NASDAQ:ALKS) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 196,108 shares of the company’s stock after buying an additional 1,577 shares during the period. Dimensional Fund Advisors LP owned 0.13% of Alkermes PLC worth $11,369,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the company. Greenwood Capital Associates LLC grew its stake in shares of Alkermes PLC by 1.1% in the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after buying an additional 41 shares during the period. World Asset Management Inc boosted its position in shares of Alkermes PLC by 1.9% during the 2nd quarter. World Asset Management Inc now owns 6,939 shares of the company’s stock worth $402,000 after purchasing an additional 128 shares during the period. Capstone Asset Management Co. boosted its position in shares of Alkermes PLC by 2.6% during the 2nd quarter. Capstone Asset Management Co. now owns 6,755 shares of the company’s stock worth $392,000 after purchasing an additional 170 shares during the period. M&T Bank Corp boosted its position in shares of Alkermes PLC by 2.9% during the 2nd quarter. M&T Bank Corp now owns 7,135 shares of the company’s stock worth $413,000 after purchasing an additional 200 shares during the period. Finally, Teachers Retirement System of The State of Kentucky boosted its position in shares of Alkermes PLC by 0.4% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 78,620 shares of the company’s stock worth $4,558,000 after purchasing an additional 292 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.
A number of research firms recently weighed in on ALKS. Zacks Investment Research raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. ValuEngine cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Barclays PLC cut shares of Alkermes PLC from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. J P Morgan Chase & Co set a $78.00 price objective on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, October 27th. Finally, UBS AG set a $54.00 price objective on shares of Alkermes PLC and gave the stock a “hold” rating in a research report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $63.55.
Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company had revenue of $217.40 million during the quarter, compared to analysts’ expectations of $231.29 million. During the same quarter last year, the company posted ($0.09) EPS. The firm’s revenue was up 20.6% compared to the same quarter last year. analysts forecast that Alkermes PLC will post -0.59 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Has $11.37 Million Stake in Alkermes PLC (ALKS)” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/16/dimensional-fund-advisors-lp-has-11-37-million-stake-in-alkermes-plc-alks.html.
In other news, SVP James M. Frates sold 20,932 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $47.58, for a total value of $995,944.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $50.77, for a total transaction of $76,155.00. Following the completion of the sale, the director now owns 9,500 shares in the company, valued at $482,315. The disclosure for this sale can be found here. Insiders sold a total of 102,498 shares of company stock valued at $5,018,010 in the last three months. 5.34% of the stock is currently owned by corporate insiders.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.